Kevin Brigle, PhD
Articles
MonumenTAL: Key Efficacy Outcomes
Meera Mohan, MD;Areyl Goff, APNP;Hashim Mann, MD;Kevin Brigle, PhD;Omar Nadeem, MD;Alexandra Distaso, NP
December 23rd 2024Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
Meera Mohan, MD;Areyl Goff, APNP;Hashim Mann, MD;Kevin Brigle, PhD;Omar Nadeem, MD;Alexandra Distaso, NP
December 23rd 202468-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.
Latest Updated Articles
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: February 13th 2015 | Updated: December 24th 2024
17-Year-Old Girl at 13 Weeks Gestation Presents With Vaginal Bleeding & Cramping
Published: December 20th 2024 | Updated: December 24th 2024
Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
